LUMATEPERONE: A NEWLY APPROVED ANTIPSYCHOTIC IN ADULTS AND POTENTIAL CONSIDERATION FOR PEDIATRIC USE: A SYSTEMIC REVIEW-BASED DISCUSSION OF CURRENT EVIDENCE

ObjectivesThe objective is to conduct a systemic review of published clinical studies assessing the current state of the evidence on the association between lumaterpone and antipsychotic-induced weight gain (AIWG).MethodsA comprehensive search of published studies on "Lumateperone" OR "ITI-007" OR "Caplyta" in English was conducted on PubMed, CINAHL Complete, APA PsychInfo, Cochrane Library, and Embase databases from inception to January 2022 employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two independent reviewers screened for all types of human studies reporting for metabolic parameters (weight, BMI, cholesterol, blood sugar, and hemoglobin A1c [HbA1c]). Animal studies and non-English language articles were excluded.ResultsPrimary search generated 77 articles, excluding 72 duplicates, of which 51 were deemed appropriate for exclusion. Full-text analysis of the remaining 26 articles concluded with 5 studies for finalized review per inclusion criteria. The 21 excluded articles were manually reviewed for relevant citations. One trial was excluded due to lack of data availability. Three randomized, double-blinded, placebo controlled clinical trials and 2 open-label trials of lumateperone were derived from this systemic review. Participants in the 2 open-label trials with lumateperone 42 mg experienced significant weight loss (mean weight loss: 0.6 kg and 2.1 kg; p < .01) while, in 3 randomized controlled trials, they showed statistically insignificant weight gain.ConclusionsThis is the first review on lumateperone and AIWG and highlights a promising metabolic profile of lumateperone. Additional research is warranted to expand our understanding of metabolic properties. The fair understanding of adult effects can be useful to child and adolescent psychiatrists, and we hope that the results presented here will guide them until we have more pediatric safety and efficacy data.PPC, PSY, SZ ObjectivesThe objective is to conduct a systemic review of published clinical studies assessing the current state of the evidence on the association between lumaterpone and antipsychotic-induced weight gain (AIWG). The objective is to conduct a systemic review of published clinical studies assessing the current state of the evidence on the association between lumaterpone and antipsychotic-induced weight gain (AIWG). MethodsA comprehensive search of published studies on "Lumateperone" OR "ITI-007" OR "Caplyta" in English was conducted on PubMed, CINAHL Complete, APA PsychInfo, Cochrane Library, and Embase databases from inception to January 2022 employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two independent reviewers screened for all types of human studies reporting for metabolic parameters (weight, BMI, cholesterol, blood sugar, and hemoglobin A1c [HbA1c]). Animal studies and non-English language articles were excluded. A comprehensive search of published studies on "Lumateperone" OR "ITI-007" OR "Caplyta" in English was conducted on PubMed, CINAHL Complete, APA PsychInfo, Cochrane Library, and Embase databases from inception to January 2022 employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two independent reviewers screened for all types of human studies reporting for metabolic parameters (weight, BMI, cholesterol, blood sugar, and hemoglobin A1c [HbA1c]). Animal studies and non-English language articles were excluded. ResultsPrimary search generated 77 articles, excluding 72 duplicates, of which 51 were deemed appropriate for exclusion. Full-text analysis of the remaining 26 articles concluded with 5 studies for finalized review per inclusion criteria. The 21 excluded articles were manually reviewed for relevant citations. One trial was excluded due to lack of data availability. Three randomized, double-blinded, placebo controlled clinical trials and 2 open-label trials of lumateperone were derived from this systemic review. Participants in the 2 open-label trials with lumateperone 42 mg experienced significant weight loss (mean weight loss: 0.6 kg and 2.1 kg; p < .01) while, in 3 randomized controlled trials, they showed statistically insignificant weight gain. Primary search generated 77 articles, excluding 72 duplicates, of which 51 were deemed appropriate for exclusion. Full-text analysis of the remaining 26 articles concluded with 5 studies for finalized review per inclusion criteria. The 21 excluded articles were manually reviewed for relevant citations. One trial was excluded due to lack of data availability. Three randomized, double-blinded, placebo controlled clinical trials and 2 open-label trials of lumateperone were derived from this systemic review. Participants in the 2 open-label trials with lumateperone 42 mg experienced significant weight loss (mean weight loss: 0.6 kg and 2.1 kg; p < .01) while, in 3 randomized controlled trials, they showed statistically insignificant weight gain. ConclusionsThis is the first review on lumateperone and AIWG and highlights a promising metabolic profile of lumateperone. Additional research is warranted to expand our understanding of metabolic properties. The fair understanding of adult effects can be useful to child and adolescent psychiatrists, and we hope that the results presented here will guide them until we have more pediatric safety and efficacy data.PPC, PSY, SZ This is the first review on lumateperone and AIWG and highlights a promising metabolic profile of lumateperone. Additional research is warranted to expand our understanding of metabolic properties. The fair understanding of adult effects can be useful to child and adolescent psychiatrists, and we hope that the results presented here will guide them until we have more pediatric safety and efficacy data.